Literature DB >> 17047075

Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality.

Melinda Butsch Kovacic1, Philip E Castle, Rolando Herrero, Mark Schiffman, Mark E Sherman, Sholom Wacholder, Ana C Rodriguez, Martha L Hutchinson, M Concepción Bratti, Allan Hildesheim, Jorge Morales, Mario Alfaro, Robert D Burk.   

Abstract

Persistent cervical infections with carcinogenic human papillomaviruses (HPV) cause virtually all cervical cancer. Cytologic abnormalities are the manifestations of HPV infections used to identify women at risk. To compare the potential of the full range of anogenital HPV genotypes to induce cytopathic effects, we examined the influences of HPV type, viral load, and age on cytopathology among 1,222 women having a single HPV type at enrollment into a 10,000-woman population-based study in Costa Rica. Cervical specimens were tested for approximately 40 HPV types by MY09/MY11 L1 primer PCR and type-specific dot blot hybridization. Types were organized by phylogenetic species and cancer risk. PCR signal strength served as a qualitative surrogate for viral load. Overall, 24.8% [95% confidence interval (95% CI), 22.4-27.3] of single prevalent HPV infections had concurrent abnormalities (atypical squamous cells or worse) ranging from 0.0% to 80.0% based on HPV type. Noncarcinogenic alpha3/alpha15 types, although highly prevalent, uncommonly caused cytologic abnormalities (13.1%; 95% CI, 9.8-17.0). In contrast, one quarter to nearly one half of infections with a single major carcinogenic species type (alpha9/alpha11/alpha7/alpha5/alpha6) produced abnormalities. Greater abnormalities were observed with increasing qualitative viral load of carcinogenic types; fewer abnormalities were observed among older women (>54 years). A high percentage (46.2%) of detected abnormalities in women infected with HPV16 or related alpha9 types were high grade or worse, consistent with strong carcinogenicity, compared with 10.7% in women infected with alpha7 types, including HPV18, a major cause of adenocarcinoma. The lack of evident severe abnormalities associated with HPV18 and related HPV types might have implications for screening for poorly detected glandular and alpha7-related lesions.

Entities:  

Mesh:

Year:  2006        PMID: 17047075     DOI: 10.1158/0008-5472.CAN-06-1812

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Longitudinal analysis of carcinogenic human papillomavirus infection and associated cytologic abnormalities in the Guanacaste natural history study: looking ahead to cotesting.

Authors:  Sarah Coseo Markt; Ana C Rodriguez; Robert D Burk; Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Martha Hutchinson; Mark Schiffman
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

2.  Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests.

Authors:  Julia C Gage; Mark Sadorra; Brandon J Lamere; Randi Kail; Carrie Aldrich; Walter Kinney; Barbara Fetterman; Thomas Lorey; Mark Schiffman; Philip E Castle
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

3.  Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure.

Authors:  Sarah E Coseo; Carolina Porras; Lori E Dodd; Allan Hildesheim; Ana Cecilia Rodriguez; Mark Schiffman; Rolando Herrero; Sholom Wacholder; Paula Gonzalez; Mark E Sherman; Silvia Jimenez; Diane Solomon; Catherine Bougelet; Leen-Jan van Doorn; Wim Quint; Mahboobeh Safaeian
Journal:  Sex Transm Dis       Date:  2011-10       Impact factor: 2.830

4.  A Suggested Approach to Simplify and Improve Cervical Screening in the United States.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  J Low Genit Tract Dis       Date:  2016-01       Impact factor: 1.925

Review 5.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

6.  No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study.

Authors:  Nicolas Wentzensen; Martha Nason; Mark Schiffman; Lori Dodd; William C Hunt; Cosette M Wheeler
Journal:  J Infect Dis       Date:  2013-10-31       Impact factor: 5.226

7.  Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3.

Authors:  Long Fu Xi; Laura A Koutsky; Philip E Castle; Cosette M Wheeler; Denise A Galloway; Constance Mao; Jesse Ho; Nancy B Kiviat
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

8.  Population-based type-specific prevalence of high-risk human papillomavirus infection in Estonia.

Authors:  Anneli Uusküla; Mart Kals; Liina Kosenkranius; Louise-Anne McNutt; Jack DeHovitz J
Journal:  BMC Infect Dis       Date:  2010-03-11       Impact factor: 3.090

9.  Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing.

Authors:  Sveinung Wergeland Sørbye; Silje Fismen; Tore Gutteberg; Elin Synnøve Mortensen
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

10.  Detection of precancerous cervical lesions is differential by human papillomavirus type.

Authors:  Mahboobeh Safaeian; Mark Schiffman; Julia Gage; Diane Solomon; Cosette M Wheeler; Philip E Castle
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.